BUZZ-Tekmira Pharmaceuticals: Acquisition to boost Hep B drugs portfolio

Mon Jan 12, 2015 7:26am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian biopharmaceutical company's U.S.-listed shares up 43 pct at $22.40 premarket

** Tekmira to buy OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods

** Implied market value of the merged company is about $750 mln, OnCore shareholders will hold 50 pct of Tekmira

** Tekmira to continue with its oncology and anti-viral programs, including Ebola

** On Sept. 22, the FDA authorized emergency use of Tekmira's Ebola treatment, but its shares have fallen 33 pct since then through Friday's close